NextGen Biomed 2025

03/10/24 - A study led by Professor Deng Hongkui at Peking University successfully treated a type 1 diabetes patient by transplanting insulin-producing islet cells derived from the patient's reprogrammed stem cells.

Unlocking Future Insights in Biomedicine Research & Development

NextGen Biomed connects thought leaders, researchers and experts with pharmaceutical & biotech representatives to discuss the latest innovations in biomedicine discovery & development.

There will be six dedicated programmes running across three full days, which together will explore the entire value chain involved in bringing next-generation biomedicines to market, making this a must-attend event for anyone working in biotherapeutics discovery, development & manufacturing.

Networking & knowledge-sharing is at the heart of what we do, with 700 pre-arranged 1-2-1 meetings and over 12 hours of networking solutions don't miss the opportunity to connect with 1,000 leaders from across pharma, biotech, regulatory and academia.

Engaging Thought Leadership
Experience over 200 interactive discussions, thought leadership debates, and collaborative roundtables, with insights from industry leaders to benchmark your research & development pipeline.

Global Technology Showcase
An international exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, a start-up zone, vibrant drinks reception, and informal gatherings to foster meaningful connections.

Start-up Zones & Awards Ceremony
Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start-up companies.

1000

leading pharma, biotech, regulatory & academic delegates

700

pre-arranged 1-2-1 meetings, facilitating business growth

hours of presentations, discussions & interactive content

hours of networking breaks, including fireside chats & refreshments

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Fernando Albericio

Professor,

University of KwaZulu-Natal

Joël Richard

Chief Development Officer,

Enterome

Kelly Loyet

Distinguished Scientist,

Genentech

Livija Deban

Chief Scientific Officer,

Prokarium

Maja Firczuk

Protein Expression Technologies Team Leader,

GSK

Marta Amaral

Group Head High Throughput Protein Engineering in Large Molecules Research,

Sanofi

Martina Ochs

Project Leader,

CEPI

Reeta Daswani

Senior Scientist,

Sixfold

Rick Hibbert

Vice President & Head of CMC Science & Technologies,

Genmab

Shahram Lavasani

Chief Executive Officer,

ImmuneBiotech AB

Sudhir Agrawal

President & Founder,

ARNAY Sciences

Tristan Vaughan

Vice President Protein Engineering,

Immunocore

Aaron John Balana

Scientist III,

Genentech

Alain Wagner

Director,

Strasbourg University

Alastair Lawson

Vice President and Immunology Fellow,

UCB

Alessandra Tolomelli

Associate Professor,

University of Bologna

Alessandro Gori

Group leader,

National Research Council of Italy

Alexey Rak

Head of Bio Structure and Biophysics,

Sanofi

Álvaro Enríquez García

Medicinal chemist,

Eli Lilly

Amita Vaidya

Principal Scientist,

Sanofi

Amy Li

Director, Drug Discovery,

T-Therapeutics Ltd

Andrew Slee

Chief Operating Officer,

Protagenic Therapeutics

Andrew Jamieson

Professor,

University of Glasgow

Andrew Buchanan

Scientist,

AstraZeneca

Aneesh Karatt-Vellatt

CoFounder & CSO,

Maxion therapeutics

Anna Hine

Professor of Protein Engineering,

Aston University

Anna Maria Papini

Full Professor and Group leader of PeptLab,

University of Florence (Italy)

Antoine Leger

Development manager,

Affilogic

Ash Otter

Principal Investigator, Emerging Pathogen Serology,

UKHSA

Aurelie Lacroix

Senior scientist,

Sixfold Bioscience

Baldur Sveinbjørnsson

Chief Scientific Officer,

Lytix Biopharma

Benjamin Lindner

Data Scientist,

Boehringer Ingelheim RCV GmbH & Co KG

Berit Olsen Krogh

Senior Research Fellow,

Lundbeck

Bryce Nelson

Head Protein and Antibody Engineering,

Orion

Callum Scott

Head of Development,

Scancell

Chris Hart

Chief Executive Officer,

Creyon Bio

Christopher Scott

Professor,

Queen's University Belfast

Christopher Coxon

Senior Lecturer, Medicinal Chemistry,

THE UNIVERSITY OF EDINBURGH

Chun Kong Mak

Oligonucleotides Analytical Scientist,

Synthon

Dan Swerdlow

Senior Director,

GSK

Dan Hardy

CEO,

Microsol

Daniel Larocque

Innovation Leader,

Sanofi Vaccines

Daniel Sejer Pedersen

Specialist,

Novo Nordisk A/S

Darko Skegro

Associate Director,

Novartis

David Craik

Professor,

The University of Queensland

David Evans

Chief Scientific Officer,

Sirnaomics

David Brockwell

Professor,

University of Leeds

David Wraith

Professor of Immunology, Director of the Institute of Immunology and Immunotherapy,

University of Birmingham

Denise Steckel

Head of Clinical Collaborations Development,

Genentech

Ed Tate

Professor,

Imperial College London

Eef Dirksen

Group Leader,

Byondis B.V.

Elisa Marelli

Research Scientsit,

Scancell

Emma Grant

Senior Analytical Development Scientist,

Immunocore

Emma Stanley

Director, Program Lead - Head of Antibody Discovery,

Mestag Therapeutics

Erik Vernet

Vice President - Scientific Data Registration,

Novo Nordisk

Fazel Shabanpoor

Lab Head Peptide And Oligonucleotide Therapeutics,

The Florey Institute of Neuroscience and Mental Health

Felix Schumacher

Program Leader Targeted Therapeutics,

Hoffmann La Roche Ltd

Francisca Wollerton

Senior Director of Protein Engineering and Novel Modalities,

AstraZeneca

Georgios Skretas

Director, Institute for Bioinnovation,

Biomedical Sciences Research Center "Alexander Fleming"

Hans Melo

Chief Executive Officer,

Menten Biotechnology Labs

Hans Van Der Vliet

Chief Scientific Officer,

LAVA Therapeutics

Helen Bright

Chief Scientific Officer,

Centauri Therapeutics

Henry Maun

Associate Director,

Genentech

Hester Van Zeeburg

PM immunomonitoring,

Mendus AB

Ian Hamley

Professor of Physical Chemistry,

University of Reading

Ijeoma Uchegbu

Professor of Pharmaceutical Nanoscience,

University College London

Ilaria Poledri

Co-Founder,

ExCulture

Immanuel Lerner

Chief Executive Officer,

Pepticom

Isabelle Sermadiras

Associate Principal Scientist,

AstraZeneca

Janos Tibor Kodra

Principal Scientist,

Novo Nordisk

Jean Ge

Patent Attorney,

Wolf Greenfield

Jenny Fitting

Head of AAV and Protein Science,

Bayer

Jill Walker

Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics,

AstraZeneca

Jim Weterings

VP Research,

Sirnaomics

John de Kruif

Executive Vice President & Chief Technology Officer,

Merus NV

John Maher

Chief Scientific Officer,

Leucid Bio

Jörg Wischhusen

Professor,

University Hospital Würzburg

Jutta Eichler

Professor,

University of Erlangen-Nurnberg

Karen Silence

Head Preclinical Product Development,

Argenx BVBA

Kevin Fitzgerald

Chief Scientific Officer,

Epsilogen

Kirsty Crame

Vice President Clinical Strategy & Development,

Medigene AG

Knud Jørgen Jensen

Professor,

Copenhagen University

Komal Kedia

Associate Principal Scientist,

Merck US

Kuda Muchandibaya

Lecturer for Supply Chain Management & Logistics,

Rhine-Waal University of Applied Sciences

Laura Starkie

Director,

UCB

Laurens Lindenburg

Principal Scientist,

Genmab

Leonardo De Maria

Principal Scientist,

AstraZeneca

Louis Diorazio

Senior Principal Scientist,

AstraZeneca

Lucas Bethge

Vice President, Group Leader Oligonucleotide Chemistry,

Silence Therapeutics

Luis Gómez-Morales

Scientific Project Manager,

Pepkon

Marc Vendrell

Professor of Translational Chemistry,

University of Edinburgh

Maria Fawaz

Associate Principal Scientist,

Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.

Marie McAvoy

Chief Scientific Officer,

Nanosyrinx

Marina Fedorova

Scientific Investigator,

GSK

Matthew Burrell

Associate Director,

AstraZeneca

Mattias Malm

Senior Scientist,

Ferring Pharmaceuticals

Michael Dyson

Vice President,

Ichnos SA

Michael Delaney

Principal Scientist,

NovoNordisk

Michal Shoshan

Founder & Chief Executive Officer,

metaLead Therapeutics AG

Michelle Wantoch

Senior Scientist,

F-star Therapeutics Inc

Mikhail Kuravskiy

Principal Scientist,

UCB

Morten Lindow

RNAHub Founder & Mission Lead,

Roche

Nadim Akhtar

Senior Principal Scientist, New Modalities,

AstraZeneca

Norbert Furtmann

Head of AI Innovation - NANOBODY® Platform,

Sanofi

Obinna Ubah

Principal Scientist,

Elasmogen Limited

Owen Vickery

Computational Biologics Design,

AstraZeneca

Paul Wassmann

Senior Principal Scientist,

Novartis AG

Paul Reid

Chief Scientific Officer,

Celtic Biotech

Pawel Stocki

Vice President R&D,

Ossianix

Pete Gough

Chief Scientific Officer,

Nimble Therapeutics

Prasun Chakraborty

Chief Executive Officer and Founder,

Genevation LTD

Rajika Perera

Chief Executive Officer,

Poseidon LLC

Rita Martello

Scientific Director, NBE DMPK Lead,

Dewpoint Therapeutics

Rodrigo Abreu

Principal Scientist,

LifeArc

Sagar Kathuria

Biophysicist - Protein Engineering,

Sanofi

Sandra Tremmel

Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,

F. Hoffmann-La Roche Ltd

Sandrien Janssens

CMC Director,

Mosanna Therapeutics

Sarah Stuart

HTC Team Leader,

GSK

Sarah Hindson

Senior Scientist,

GSK

Saul Martinez Montero

Senior Director, RNA Therapeutics,

Dyne Therapeutics

Simon Krah

Associate Director,

Merck Healthcare KgaA

Simon Plyte

Chief Scientific Officer,

Biomunex Pharmaceuticals

Simon Hufton

Section Head Molecular Immunology, Division of Biotherapeutics,

MHRA

Sonia Macia

Chief Medical Officer,

Aromics Therapeutics

Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy,

King's College London

Sritama Bose

Head of Chemistry Research and Innovation,

Nucleic Acid Therapy Accelerator MRC

Stefan Zielonka

Director and Head of Antibody Discovery and Protein Engineering,

Merck Healthcare KGaA & Technische Universität Darmstadt

Stephen Miller

Principal Scientist,

Genentech

Steve Hood

Senior Director, Oligonucleotide ADME Strategy, DMPK,

GSK

Steven Schmitt

Co-Founder & Chief Executive Officer,

Myria Biosciences

Sue Charlton

Head of Clinical Evaluation,

UKHSA

Talip Ucar

Senior Director - AI Research,

AstraZeneca

Tatyana Ponomaryov

Principal Scientist,

Plasticell Limited

Thomas Kraft

Principal Scientist,

Roche

Tim Hickling

Investigative Safety and Immunosafety Chapter Lead,

Hoffmann La Roche Ltd

Tomáš Hanke

Professor,

University of Oxford

Vincent Dewar

Head of Immunoassay,

GSK

Vincenzo de Filippis

Associate Professor Biochemistry,

University of Padova

Vladimir Gligorijevic

Senior Director of AI/ML,

Genentech

Walter Cabri

Professor,

University of Bologna

Wen Chang

Associate Vice President Discovery and Early Development,

AcuraStem

Will Nesbit

Director - Process Chemistry, CMC,

Bicycle Therapeutics

Yi Yang

Principal Scientist,

Ferring Pharmaceuticals A/S

Zahra Rattray

Senior Lecturer,

University of Strathclyde

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

In-Person Services Digital Marketing Services

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

Advanced Therapies Specialist Team Leader,
Genscript

Biologics 2024 has been one of the best events I have attended so far in my career.

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Impressed by the effort to bring people together.

Business Development Director,

Bioassay

Nice set-up, with good support for exhibitors

Director of Client Relations,

ImmunoPrecise

The start-up zone provides a unique opportunity to for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals.

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans.

There are two options, based on the size of your organisation with prices starting from £1,500 (+VAT).

For further information and to get started submit the application form below.

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13^th January 2025 in the below category:

Protein/Antibody Engineering
Bioanalysis & Characterisation
Next Generation Biotherapeutics
Peptides Chemistry & Therapeutics
Oligonucleotides Chemistry & Therapeutics
Sustainable Chemistry & Manufacturing

Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13^th January 2025
ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows:

Register and submit an abstract by 13^th January 2025 using the registration link to the left on this page
Once registered you will be provided with the online abstract submission form
Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)
The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event
The winners’ 10-minute oral presentations will take place during the networking drinks on day 2

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights.

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of NextGen Biomed 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.